3Loots MA, Lamme EN, Zeegelaar J, et al. Differences in cellular infiltrate and extracellularmatrixof chronic diabetic and venousul- cers versus acute wounds [ J]. J. Invest. Derm, 1998, 111: 850- 857.
4i American Diabetes Association. Standards of medical care in dia- betes - 2007[ J]. Diabetes Care,2007,30(suppl) : 12.
5Chmidt AM. Cell~ar receptors for advanced glycation end products [J]. Arterioscler Thromb, 1994,14(15) : 1521.
6Radkin P. Risk factors for the development of complications of di- abetic complications[J]. J Diabetes Comp, 1994,8(2) : 195.
7Tsai SC, Bttrnalds TG. Aldose reductase inhibitors: an up-date [ J ]. Ann Phannacotherapy, 1993,27 (7) : 751.
8Baba M. Progress in therapy for and diagnosis of diabetic neuropa- thies[J]. Nippon Naika Gakkai Zasshi, 2009, 98 (4) : 779-786.
9Vareniuk I, Pacher P, Paylor LA, et al. Peripheral neuropathy in mice with neuronal nitric oxide synthase gene deficiency [J]. Int J Mol Med, 2009, 23(5): 571-580.
10Jin XG, He SQ, Yan XT, et al. Variants of neural nitric oxide synthase in the spinal cord of neuropathic rats and their effects on nuclear factor-kappaB (NF-kappaB) activity in PC12 Cells [J]. J Pain, 2009,10(1): 80-89.
